Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3048% below fair value

$1.71+0.09 (+5.56%)

Close on Nov 13, 2026Market cap $14.10MP/E –Yield –

Lipocine EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Lipocine's EV/EBITDA was 3.9× on Jan 31, 2023.

Period	Period end	Value	Change (pts)
2023	Jan 31, 2023	3.9×	+3.6
2022	Dec 30, 2022	0.3×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LPCN.

Revenue growth-13.4% · median 37.9%

Operating margin-269.1% · median -1477.0%

Net margin-249.2% · median -1483.8%

Advertisement
300 × 250

See a number that looks wrong?